published_or_final_version / Medical Sciences / Master / Master of Medical Sciences

The aim of this thesis is to evaluate the role of the extracellular environment in regulating breast cancer cell morphological and invasive characteristics. In vitro experiments of breast cancer cell lines in three dimensional matrices, which afford control over variables of interest while maintaining physiological relevance, were utilized for this purpose. We evaluated the sensitivity of cell morphology to the dimensionality, biochemistry, and mechanical properties of the extracellular environment as well as the reciprocal effects cells display when remodeling the extracellular environment during invasion. Chapter 1 introduces background material on breast cancer development, classification systems, and in vitro methods of research. Chapter 2 describes protocols for cell care and experiments used in these studies. In chapter 3, we explore the role of fibrillar collagen I environments in breast cancer cell invasion. This was motivated by previous research that has associated high breast tissue density with breast cancer risk and poor prognosis as well as tissue stiffness with cancer cell aggressiveness. Breast cancer cells were found to regain an invasive phenotype in sterically constrained environments when the extracellular matrix included a fibrillar component. In chapter 4, the relationship between cell morphology and invasive behavior in various dimensional contexts was assessed. Anecdotal evidence has shown stellate morphology may be associated with epithelial to mesenchymal transition and invasive capacity in cancer cells. Differences in the dimensionality and biochemistry of the environment resulted in changes to cell aggregate morphology. Although morphology did not predict invasive capacity as measured by spheroid invasion in collagen I, invasion was found to correlate with cancer-related gene expression profiling, suggesting the ability of cancer cells to utilize more than one mode of invasion. Chapter 5 explores to what degree the presence of invasive cells can give rise to invasive behavior from noninvasive cells. Segregation of cell subtypes during co-culture spheroid formation was found to be altered in the presence of BME. When implanted into collagen gels, invasive cell lines that generate structural changes to the extracellular matrix on their own were able to confer invasive behavior to otherwise noninvasive cell lines in some cases. Chapter 6 summarizes these findings and suggests further studies. Appendix 1 lists useful abbreviations. In Appendices 2 and 3, codes for ImageJ and Matlab-based analyses are recorded. Through this work, we see how cell morphology and invasive capacity are influenced by the extracellular environment. Cells that can interact with components of the extracellular matrix through matrix-specific integrins show a range of capacities for remodeling the extracellular environment, which in turn plays a role in invasive capacity. We anticipate that enhanced understanding of the role of the extracellular environment in regulating cell morphology and invasive behavior will lead to advances in the study of cell locomotion as well as in cancer research, diagnosis, and treatment.

published_or_final_version / Pharmacology and Pharmacy / Doctoral / Doctor of Philosophy

Angiogenesis is one of the essential hallmarks of cancer, typically breast cancer. Signaling from VEGFR-2 is necessary for the execution of VEGF-induced proliferation, migration, and tube formation of cultured endothelial cells in vitro and the onset of angiogenesis on tumors in vivo. Ellagic acid is a naturally existing small molecular polyphenol widely found in fruits and vegetables. It was reported that ellagic aicd interfered with some angiogenesis-dependent pathologies. Yet the mechanisms involved were not fully understood. Thus we analyzed its anti-angiogenesis effects and mechanisms on human breast cancer utilizing in vitro and in vivo methodologies. Besides, the in silico analysis was carried out to further analyze the structure-based interaction between ellagic aicd and VEGFR-2. The influences of ellagic aicd on VEGF-induced endothelial cells were studied by proliferation, tube formation and migration in vitro experiments. Kinase activity assay and western blotting were utilized to explore the effects of ellagic aicd on VEGFR-2 induced signaling pathway. Organ-based chick aortic ring model, in vivo Chorioallantoic membrane model and in vivo breast cancer xenografts were built to determine the anti-angiogenesis effects of ellagic aicd. Besides, software LigandFit algorithm in Discovery Studio 2.1 (Accelrys Inc., San Diego, CA) was applied to further understand the structure-based interaction between ellagic aicd and VEGFR-2. We found that ellagic aicd impeded a series of VEGF-induced angiogenesis processes including proliferation, migration and tube formation of endothelial cells. Besides, it directly inhibited VEGFR-2 tyrosine kinase activity and its downstream signaling pathways including MAPK and PI3K/Akt on endothelial cells. Ellagic aicd also obviously inhibited sprouts formation from chicken aorta and neo-vessel formation in chick chorioallantoic membrane. The growth and the P-VEGFR2 expression in breast tumors treated with ellagic aicd were also significantly suppressed. In the molecular docking simulation experiment, the structure-based interaction of VEGFR-2 with ellagic acid was found to be stable conformation by hydrogen bonds within residues Lys866 and Glu883 as well as by π–π interactions within residue Phe1045 at ATP binding pocket of VEGFR-2 catalytic domain. Taken together, ellagic aicd could exert anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. / published_or_final_version / Chinese Medicine / Master / Master of Philosophy

No description available.

published_or_final_version / Biological Sciences / Master / Master of Philosophy

Metastasis is the primary cause of mortality in women with breast cancer. Recently, elevated serum levels of a glycoprotein known as chitinase-3 likeprotein- 1 (CHI3L1) has been correlated with poor prognosis and shorter survival of patients with cancer and inflammatory diseases. The biological and physiological functions of CHI3L1 in tumor progression have not yet been elucidated. In this document, we describe the role of CHI3L1 in tumor growth and metastasis and its relationship with inflammation. Using well-established models of breast cancer, we show that CHI3L1 is increased in the serum of tumor bearing mice. We found that CHI3L1 levels are increased at both the “pre-metastatic” and “metastatic stage” and that tumor cells, splenic, alveolar and interstitial macrophages; and myeloid derived population produce CHI3L1. Furthermore, we demonstrated that CHI3L1 has an inhibitory role on the expression of interferon-gamma (IFN γ) by T cells, while enhancing the production of pro-inflammatory mediators by macrophages such as Cchemokine ligand 2 (CCL2/MCP-1), Chemokine CX motif ligand 2 (CXCL2/IL-8) and matrix metalloproteinase-9 (MMP-9), all of which promote tumor growth and metastasis. We demonstrated that in vivo treatment of tumor-bearing mice with chitin microparticles, a TH1 adjuvant and a substrate for CHI3L1, promoted immune effector functions with increased production of IFN-γ but decreased CCL2/MCP-1, CXCL2/IL-8 and MMP-9 expression by splenic and pulmonary macrophages. Significantly, in vivo administration of chitin microparticles decreased tumor growth and pulmonary metastasis in mammary tumor bearing mice. These results suggest that CHI3L1 may play a role in tumor progression. Inflammation plays a pivotal role during tumor progression and metastasis by promoting the production of pro-inflammatory molecules such as CHI3L1. However, little is known about how CHI3L1 expression can affect secondary sites to enhance metastasis. In these studies, we demonstrated that CHI3L1 alters the cellular composition and inflammatory mediators that aid in the establishment of a metastatic niche for the support of infiltrating tumor cells leading to accelerated tumor progression. Since previous studies showed that CHI3L1 modulates inflammation, we determined the role of CHI3L1 in the context of pre-existing inflammation and metastasis. We found that CHI3L1 deficient mice with preexisting inflammation had decreased pro-inflammatory mediators, and significant reduction in tumor volume and metastasis compared to wild type controls. Preexisting inflammation and CHI3L1 may be driving the establishment of a premetastatic milieu in the lungs and aiding in the establishment of metastasis. Understanding the role of CHI3L1 in inflammation during tumor progression could result in the design of targeted therapies for breast cancer patients. / Includes bibliography. / Dissertation (Ph.D.)--Florida Atlantic University, 2015. / FAU Electronic Theses and Dissertations Collection

[Truncated abstract] Introduction: Breast cancer is a heterogeneous disease, resulting in very different outcomes for women with apparently similar tumour characteristics. In order for patients to have optimal treatment, a better understanding of the molecular nature of their disease is required. Aims: The aims of this thesis were: 1) To determine whether methylation of RARβ2, ER, CDH1, BRCA1, CCND2, p16 and TWIST genes are associated with phenotypic features of breast cancer and the prognostic significance of methylation of these genes. 2) To investigate for possible associations between the frequency of methylation at RARβ2, CDH1, ER, BRCA1, CCND2, p16 and TWIST genes and the presence of germ-line variants in the TS, MTHFR, MS, CBS, MTHFD1 and DNMT3B genes, as well as for possible correlations between these polymorphisms and clincopathological features of breast cancer including patient outcome. 3) To determine whether PIK3CA mutations determined clinical phenotype and the prognostic significance of PIK3CA mutations in a large and well characterized cohort of breast cancer patients. Methods: A large and well characterized series of primary breast tumours were selected for methylation of RARβ2, ER, CDH1, BRCA1, CCND2, p16 and TWIST genes using MSP, and for polymorphisms in TS, MTHFR, MS, CBS, MTHFD1 and DNMT3B genes using PCR, PCR-RFLP and PCR-SSCP. Mutations to PIK3CA were detected using F-SSCP. Results and Conclusions: Methylation frequencies ranged from 11% for CCND2 to 84% for ER. More frequent hypermethylation was observed in tumours with poor histological differentiation compared to those with well/moderate differentiation, as well as trends for association with larger tumour size and mutant TP53. Tumours with ER and CDH1 methylation were associated with significantly lower hormone receptor levels, younger age at diagnosis and the presence of mutant p53. TWIST methylation is firstly reported to be associated with significantly older patient age at diagnosis and larger tumour size. Our data suggests that gene methylation may be linked to various pathological features of breast cancer. However, there appears to be little support for a distinctive CpG island methylator phenotype in breast cancer.

Indiana University-Purdue University Indianapolis (IUPUI) / Breast cancer remains the most prevalent malignancy diagnosed in women. More than two thirds of all diagnosed breast cancers are estrogen receptor (ER)-positive and are dependent on estrogen signaling. Drugs for the treatment of ER-positive breast cancer can be divided into three classes: selective estrogen receptor modulators (SERMs), selective estrogen receptor down-regulators (SERDs) and aromatase inhibitors (AIs). However, the efficacy and safety of SERMs, SERDs and AIs are compromised by side effects or tumor resistance. One possible way of improving treatment efficacy and safety profiles is to develop agents with dual aromatase inhibitory and ER modulatory activity. Over the past 30 years, tamoxifen, a SERM, has become the most widely used drug for the adjuvant treatment of breast cancer. The metabolism of tamoxifen has a complex profile involving both active and inactive metabolites, among which endoxifen, 4-hydroxytamoxifen (4-HT) and norendoxifen (Nor) have been shown to have ER modulatory activity. Previous studies have also shown that norendoxifen is a potent AI in vitro. These preliminary studies support the utilization of tamoxifen metabolites as lead compounds for the development of dual AI/SERM(D) agents. Hydroxynorendoxifen (Hdn) was identified as a novel tamoxifen metabolite, with an average plasma concentration of 0.82 nM. Nor and Hdn were potent and relatively selective AIs, with Kis of 70 nM and 20 nM, respectively. Nor and Hdn have high binding affinity for ER-α and ER-β, with EC50 values less than 35 nM. Nor and Hdn can inhibit breast cancer cell proliferation with high potency, with IG50s of 25 nM and 9 nM, respectively. Nor and Hdn can suppress progesterone receptor (PGR) mRNA expression level by reducing it by 68% and 86%. Moreover, a series of Nor analogues were shown to have both potent aromatase inhibitory activity and high ERs binding affinity. Results from this dissertation will contribute to three aspects: 1) the identification of Hdn as a tamoxifen metabolite illustrated a more comprehensive metabolism profile of tamoxifen; 2) the data suggest Nor and Hdn possess dual aromatase inhibitory and ER antagonistic activity; 3) a series of Nor analogues were characterized as lead compounds for the development of dual AI/SERM(D) agents.